Changes in airway inflammation with pseudomonas eradication in early cystic fibrosis

被引:11
|
作者
Garratt, Luke W. [1 ]
Breuer, Oded [1 ,2 ,3 ]
Schofield, Craig J. [1 ]
McLean, Samantha A. [1 ]
Laucirica, Daniel R. [1 ,4 ]
Tirouvanziam, Rabindra [5 ,6 ]
Clements, Barry S. [1 ,3 ]
Kicic, Anthony [1 ,3 ,4 ,7 ,8 ]
Ranganathan, Sarath [9 ,10 ,11 ]
Stick, Stephen M. [1 ,3 ,4 ]
机构
[1] Univ Western Australia, Wal Yan Resp Res Ctr, Telethon Kids Inst, Nedlands, WA, Australia
[2] Hadassah Hebrew Univ, Dept Pediat, Pediat Pulm Unit, Med Ctr, Jerusalem, Israel
[3] Perth Childrens Hosp, Dept Resp & Sleep Med, Nedlands, WA, Australia
[4] Univ Western Australia, Fac Hlth & Med Sci, Nedlands, WA, Australia
[5] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA
[6] Childrens Healthcare Atlanta, Ctr CF & Airways Dis Res, Atlanta, GA USA
[7] Univ Western Australia, Ctr Cell Therapy & Regenerat Med, Sch Med & Pharmacol, Subiaco, WA, Australia
[8] CurtinUniv, Sch Publ Hlth, Occupat & Environm, Bentley, WA, Australia
[9] Royal Childrens Hosp, Dept Resp Med, Parkville, Vic, Australia
[10] Murdoch Childrens Res Inst, Parkville, Vic, Australia
[11] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
P; aeruginosa; Inflammation; Neutrophil elastase; CT; Bronchiectasis; YOUNG-CHILDREN; NEUTROPHIL ELASTASE; AERUGINOSA INFECTION; PULMONARY-FUNCTION; SPUTUM BIOMARKERS; RISK-FACTORS; THERAPY; DISEASE; BRONCHIECTASIS; EXACERBATIONS;
D O I
10.1016/j.jcf.2020.12.015
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Neutrophil elastase is a significant risk factor for structural lung disease in cystic fibrosis, and Pseudomonas aeruginosa airway infection is linked with neutrophilic inflammation and substantial respiratory morbidity. We aimed to evaluate how neutrophil elastase (NE) activity changes after P. aeruginosa eradication and influences early disease outcomes. Methods: We assessed participants in the AREST CF cohort between 20 0 0 and 2018 who had P. aeruginosa cultured from their routine annual bronchoalveolar lavage (BAL) fluid and who underwent eradication treatment and a post eradication BAL. Factors associated with persistent P. aeruginosa infection, persistent neutrophilic inflammation following eradication and worse structural lung disease one year post-eradication were evaluated. Results: Eighty-eight episodes (3 months to 6 years old) of P. aeruginosa infection were studied. Eradication was successful in 84.1% of episodes. Median activity of NE was significantly reduced post-eradication from 9.15 to 3.4 nM ( p = 0.008) but persisted in 33 subjects. High post-eradication NE levels were associated with an increased risk for P. aeruginosa infection in the next annual visit (odds ratio = 1.7, 95% confidence interval 1.1-2.7, p = 0.014). Post-eradication NE levels (difference, 0.8; 95% confidence interval, 0.1-1.5) and baseline bronchiectasis computed tomography (CT) score (difference, 0.4; 95% confidence interval, 0.1-0.8) were the best predictors of bronchiectasis progression within 1 year (backward stepwise linear regression model, R 2 = 0.608, P < 0.001), independent of eradication. Conclusion: In children with CF, NE activity may persist following successful P. aeruginosa eradication and is significantly associated with bronchiectasis progression. Evaluating strategies to diminish neutrophilic inflammation is essential for improving long-term outcomes. (c) 2020 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:941 / 948
页数:8
相关论文
共 50 条
  • [41] EFFECTIVENESS OF A PSEUDOMONAS AERUGINOSA ERADICATION PROTOCOL IN CHILDREN WITH CYSTIC FIBROSIS
    Blanchard, A. C.
    Horton, E.
    Stanojevic, S.
    Taylor, L.
    Waters, V. J.
    Ratjen, F.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 319 - 319
  • [42] Effects of a Pseudomonas aeruginosa eradication policy in a cystic fibrosis clinic
    Davidson, A. George F.
    Chilvers, Mark A.
    Lillquist, Yolanda P.
    CURRENT OPINION IN PULMONARY MEDICINE, 2012, 18 (06) : 615 - 621
  • [43] Eradication treatment of Pseudomonas Aeruginosa in pediatric patients with Cystic Fibrosis
    Gulieva, A.
    Yegit, C. Yilmaz
    Yanaz, M.
    Kalyoncu, M.
    Selcuk, M.
    Tastan, G.
    Suzer, B.
    Ergenekon, P.
    Eralp, E. Erdem
    Gokdemir, Y.
    Karakoc, F.
    Karadag, B.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [44] PSEUDOMONAS AERUGINOSA ERADICATION IN CYSTIC FIBROSIS PATIENTS: A RETROSPECTIVE REVIEW
    Gerwin, A. M.
    Britton, L. J.
    Benner, K.
    Tofil, N.
    Guiterrez, H.
    Troxler, R. B.
    Hoover, W. C.
    PEDIATRIC PULMONOLOGY, 2009, : 339 - 339
  • [45] Eradication of initial pseudomonas aeruginosa colonization in patients with cystic fibrosis
    Griese, M
    Müller, I
    Reinhardt, D
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2002, 7 (02) : 79 - 80
  • [46] Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway
    Moreau-Marquis, Sophie
    Stanton, Bruce A.
    O'Toole, George A.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2008, 21 (04) : 595 - 599
  • [47] TOBRAMYCIN SUSCEPTIBILITY OF PSEUDOMONAS AERUGINOSA CYSTIC FIBROSIS ISOLATES USING STANDARD & BIOFILM METHODS: RELATIONSHIP WITH ERADICATION & INFLAMMATION
    Hoffman, L. R.
    Moskowitz, S. M.
    Foster, J. M.
    Emerson, J.
    Burns, J. L.
    Gibson, R. L.
    PEDIATRIC PULMONOLOGY, 2010, : 336 - 337
  • [48] Metabolomic Evaluation of Neutrophilic Airway Inflammation in Cystic Fibrosis
    Esther, Charles R., Jr.
    Coakley, Raymond D.
    Henderson, Ashley G.
    Zhou, Yi-Hui
    Wright, Fred A.
    Boucher, Richard C.
    CHEST, 2015, 148 (02) : 507 - 515
  • [49] Infection and Inflammation MUC up the Cystic Fibrosis Airway
    Ma, Jonathan
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2022, 67 (02) : 153 - 154
  • [50] Cystic fibrosis airway epithelium remodelling: involvement of inflammation
    Adam, Damien
    Roux-Delrieu, Jacqueline
    Luczka, Emilie
    Bonnomet, Arnaud
    Lesage, Julien
    Merol, Jean-Claude
    Polette, Myriam
    Abely, Michel
    Coraux, Christelle
    JOURNAL OF PATHOLOGY, 2015, 235 (03): : 408 - 419